Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes

(2011) R. R. Wing et al.   DIABETES CARE

Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivation

(2011) J. Logue et al.   HEART

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

(2011) Kishore M Gadde et al.   LANCET

Waist Circumference as Compared with Body-Mass Index in Predicting Mortality from Specific Causes

(2011) Michael F. Leitzmann et al.   PLoS One

The Pharmacological Treatment and Management of Obesity

(2011) Syed Sufyan Hussain et al.   POSTGRADUATE MEDICINE

Standards of Medical Care in Diabetes--2011

(2010)   DIABETES CARE

Prevalence and Trends in Obesity Among US Adults, 1999-2008

(2010) Katherine M. Flegal   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Obesity, weight loss and conditional cardiovascular risk factors

(2010) T. Tzotzas et al.   Obesity Reviews

Harmonizing the Metabolic Syndrome

(2009) K.G.M.M. Alberti et al.   CIRCULATION

The Medical Risks of Obesity

(2009) Xavier Pi-Sunyer   POSTGRADUATE MEDICINE